These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11496864)

  • 1. Fluvoxamine for the treatment of anxiety disorders in children and adolescents.
    Isaacs E
    N Engl J Med; 2001 Aug; 345(6):466-7. PubMed ID: 11496864
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
    N Engl J Med; 2001 Apr; 344(17):1279-85. PubMed ID: 11323729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment of anxiety disorders in children.
    Coyle JT
    N Engl J Med; 2001 Apr; 344(17):1326-7. PubMed ID: 11320394
    [No Abstract]   [Full Text] [Related]  

  • 5. Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy.
    Brzozowska A; Werner B
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):591-2. PubMed ID: 19877986
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended-release fluvoxamine (Luvox CR).
    Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The luvox debate.
    Dickinson A
    Time; 2001 May; 157(18):76. PubMed ID: 11373801
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluvoxamine approved for treating OCD in children.
    J Psychosoc Nurs Ment Health Serv; 2001 Jan; 39(1):11. PubMed ID: 11197991
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacologic treatment of anxiety disorders in children and adolescents.
    Velosa JF; Riddle MA
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):119-33. PubMed ID: 10674193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin syndrome after a single dose of fluvoxamine.
    Mullins ME; Horowitz BZ
    Ann Emerg Med; 1999 Dec; 34(6):806-7. PubMed ID: 10577418
    [No Abstract]   [Full Text] [Related]  

  • 13. Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
    Jaffe RJ; Juneja NS; Juneja NS; Jaffe RJ; Coffey BJ
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):488-490. PubMed ID: 30226805
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
    Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
    Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine for phobia of storms.
    Balon R
    Acta Psychiatr Scand; 1999 Sep; 100(3):244-5; discussion 245-6. PubMed ID: 10493092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
    den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.
    Abikoff H; McGough J; Vitiello B; McCracken J; Davies M; Walkup J; Riddle M; Oatis M; Greenhill L; Skrobala A; March J; Gammon P; Robinson J; Lazell R; McMahon DJ; Ritz L;
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):418-27. PubMed ID: 15843763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl.
    Vlatka BM; Branka AM; Branimir M
    Gen Hosp Psychiatry; 2010; 32(4):e9-e10. PubMed ID: 20633737
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review.
    Murphy TK; Bengtson MA; Tan JY; Carbonell E; Levin GM
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S47-63. PubMed ID: 11110019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.